DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Gordon syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGordon syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gordon syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
piezo type mechanosensitive ion channel component 2 (PIEZO2) — PIEZO2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9VEE · 3.36 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Two distinct conditions share the name Gordon syndrome. One is a skeletal disorder caused by pathogenic variants in PIEZO2, characterised by camptodactyly, cleft palate, and talipes equinovarus. A 2014 review of that form reported two new cases, both of which also had congenital myopathy, and one of whom developed malignant hyperthermia; the authors stated these were the first reported cases linking Gordon syndrome with either congenital myopathy or malignant hyperthermia. A 2020 case report described a Saudi female with features of Marden–Walker syndrome who carried a novel de novo likely pathogenic variant in PIEZO2, lending support to the link between that gene and Marden–Walker syndrome.
The other condition called Gordon syndrome is type 2 pseudohypoaldosteronism, a rare familial hypertension with autosomal dominant inheritance in most cases. A 2020 case report of an 11-year-old boy described the characteristic triad: hypertension, hyperkalaemia, and normal glomerular filtration rate, with low aldosterone and reduced renin activity under normal salt loading. Metabolic acidosis (type IV renal tubular acidosis) may occur. The boy was treated with a thiazide diuretic, which was clinically effective, and genetic analysis confirmed the diagnosis.
No drug other than thiazide diuretics is mentioned in any of these abstracts. No controlled trial, no survival data, no response rates, and no sample sizes beyond single cases or two-patient series are reported. The skeletal form of Gordon syndrome has no described pharmacological intervention in these papers. What is missing for both forms is any systematic trial, any patient stratification by genotype, and any funding for natural history studies or drug development.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2020 · 11 citations
Confirming the involvement of <scp><i>PIEZO2</i></scp> in the etiology of <scp>Marden–Walker</scp> syndrome
AbstractPathogenic heterozygous variants in PIEZO2 typically cause distal arthrogryposis type 5 (DA5) and the closely related Gordon syndrome (GS). Only one case of PIEZO2-related Marden-Walker syndrome (MWS) has been reported to date. We report the phenotypic features of a Saudi female patient with features consistent with MWS in whom we identified a novel de novo likely pathogenic variant in PIEZO2. Our case lends support to the link between PIEZO2 and MWS.
The Cleft Palate-Craniofacial Journal · 2014 · 4 citations
Gordon Syndrome: Literature Review and a Report of Two Cases
AbstractThe aim of this article is to publish a literature review and report on two new cases of Gordon syndrome (GS), a rare syndrome documented to have an autosomal dominant inheritance pattern or to occur sporadically; it is characterized by camptodactyly, cleft palate, and talipes equinovarus. We report two exceptional cases of GS where both patients were also diagnosed with congenital myopathy, and one developed malignant hyperthermia. These are the first two cases reported where patients were diagnosed with both GS and congenital myopathy or where GS is associated with malignant hyperthermia.
Pediatria Polska · 2020 · 0 citations · open access
Gordon syndrome in an 11-year-old boy: long-term follow-up
AbstractGordon syndrome, or type 2 pseudohypoaldosteronism, is a rare familial occurring hypertension, in most cases inherited in an autosomal dominant manner. It is characterised by coexisting hyperkalaemia, which is not found in other monogenic forms of hypertension. In addition, in this syndrome aldosterone levels are usually low, and renin activity is reduced under normal salt loading. Renal function, assessed on the basis of glomerular filtration rate, is normal, but metabolic acidosis -type IV renal tubular acidosis -may occur. The authors would like to present the case of an 11-year-old boy in whom the above-described symptoms of Gordon syndrome were observed; clinically effective thiazide diuretic therapy, and subsequent genetic analysis confirmed the diagnosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
